PT - JOURNAL ARTICLE AU - Wang, Ming AU - Fu, Aisi AU - Hu, Ben AU - Tong, Yongqing AU - Liu, Ran AU - Gu, Jiashuang AU - Liu, Jianghao AU - Jiang, Wen AU - Shen, Gaigai AU - Zhao, Wanxu AU - Men, Dong AU - Deng, Zixin AU - Yu, Lilei AU - Li, Yan AU - Liu, Tiangang TI - Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses AID - 10.1101/2020.03.04.20029538 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.04.20029538 4099 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20029538.short 4100 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20029538.full AB - The ongoing novel coronavirus pneumonia COVID-19 outbreak in Wuhan, China, has engendered numerous cases of infection and death. COVID-19 diagnosis relies upon nucleic acid detection; however, current recommended methods exhibit high false-negative rates, low sensitivity, and cannot identify other respiratory virus infections, thereby resulting patient misdiagnosis and impeding epidemic containment. Combining the advantages of target amplification and long-read, real-time nanopore sequencing, we developed nanopore target sequencing (NTS) to detect SARS- CoV-2 and other respiratory viruses simultaneously within 6–10 h. Parallel testing with approved qPCR kits of SARS-CoV-2 and NTS using 61 nucleic acid samples from suspected COVID-19 cases confirmed that NTS identified more infected patients as positive, and could also monitor for mutated nucleic acid sequence or other respiratory virus infection in the test sample. NTS is thus suitable for contemporary COVID-19 diagnosis; moreover, this platform can be further extended for diagnosing other viruses or pathogens.Competing Interest StatementWuhan Dgensee Clinical Laboratory Co., Ltd have applied patents on this new strategy.Funding StatementThis project was supported by Wuhan Dgensee Clinical Laboratory Co., Ltd.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or used during the study appear in the submitted article.